Interview with Dr Rabinder Buttar By Gareth Macdonald, 08-Feb-2010, duration 04:41 |
Improving healthcare infrastructure across the region and a large treatment-naïve patient population makes the Middle East and North Africa (MENA) an increasingly attractive destination for drug trials says ClinTec CEO Rabinder Buttar.
Dr Buttar, who spoke with Outsoucing-pharma a few days after ClinTec reported a 45 per cent hike in 2009 sales, said that while the MENA trials sector is small on a global scale, the region has all the right elements for considerable growth.
She cited the growing number of new high-tech hospitals, the highly educated medical workforce and the increased presence of global regulators among MENA’s attractive features for trial sponsors.
Related topics: Globalisation, Clinical evolution, Clinical Development, Phase I-II, Phase III-IV, Regulatory affairs
Copyright - Unless otherwise stated all contents of this web site are © 2000/2010 - Decision News Media SAS - All Rights Reserved - For permission to reproduce any contents of this web site, please email our Syndication department: Administration & Finance - Full details for the use of materials on this site can be found in the Terms & Conditions
Christopher Ung
VP of strategic business and operations, Quintiles
Jay Norman
President of the consulting group, Quintiles
Jeff Trotter
executive vice president Phase IV development, PharmaNet
Roger Price
Director of business development, Europe, ClinStar
Jeff Huntsman
VP sales and marketing, Liquent
Alistair Macdonald
Executive Vice President, Strategic Development, INC Research
John Blakeley
Executive VP sales and marketing, E Research Technology
Michael Rosenberg
CEO , Health Decisions
Kate Wilber
Director of European Regulatory Services, Image Solutions
David Backer
Director of Business Development and Marketing, SAFC Pharma
There are signs that 2010 will be a...
Mark Crane
VP business development and marketing, Ricerca
Professor Peter Crome
European Union PREDICT group, Keele University, UK
Michael Rosenberg
CEO, Health Decisions
Paul Cowan
CEO, Quotient Bioresearch
AAPS 2009 has drawn to a close but...
Following the first full day of AAPS 2009...
Gerben Moolhuizen, OctoPlus and Hans Baumeister, Glycotope
James Easson, Merk KGaA, Shirley Dann, SCM Pharma
As CPhI 2009 draws to a close we...
David Backer
Business development and marketing director, SAFC Pharma
We look ahead to CPhI 2009 which takes...
Paul Branthwaite
Senior partner, TranScrip Partners
Eric Carlson, vice president, life science technology
Matthew Pino, director, business operations, Symyx
Mark Egerton
Managing director, Quotient Clinical
Sari Hakli
Sales Manager, Pharmaceutical Solutions , Stora Enso
Welcome to this seasonal holiday video from Decision...
Don’t miss this video interview with Robert...
Jeffrey Crangle
General manager, PTI Packaging Systems
Jennifer Riter
Director of analytical and technical services, West Pharmaceutical Services
Paul Chapman
VP, Downstream Processing, Millipore
Wesley Wheeler
Chief Executive Officer & President, Patheon
Javier Rojo, executive VP of sales and marketing
Pedro Bezares, product development manager, Amcor Flexibles
The Decision News Media team would like to...
Tim Bölke
Head of excipient taskforce, European Fine Chemicals Group
Mike Harris
Managing Director UK and Ireland, Sigma Aldrich, Vice President ,...
